The FDA has approved the drug to treat rheumatoid arthritis, Actemra, the only product on the market that will actively prevent this inflammatory process at the source. Although there are 9 biologically designed products on the market that will treat certain forms of arthritis, Actemra is the only drug that is targeting the disease at the molecular level.

Actemra prevent the arthritis by effectively halting the processing ability of a specific molecular protein known as Interleukin 6 which is known to cause inflammation in the bones and joints of the human body.

Researchers at the National Institutes of Health and other institutions have discovered the third in a sequence of genes that accounts for previously unexplained forms of osteogenesis imperfecta (OI), a genetic condition that weakens bones and results in frequent fractures. The newly identified gene contains the information needed to make the protein Cyclophilin B. This protein is part of a complex of three proteins that modifies collagen, folding it into a precise molecular configuration.

For the full story, Click Here

Biocomposites has launched geneX ds, a dual syringe mixing and minimally invasive delivery system containing geneX, the unique resorbable bone graft material with a negative surface charge. The powder and liquid components of geneX are provided pre-packed in separate syringes. The syringes connect together and allow a faster, simpler and cleaner way for mixing geneX. The resulting setting paste can then be delivered through a 3.15″ dispenser (included).

For the full story, Click Here

According to a new study accepted for publication in The Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (JCEM), fat mass is important in increasing bone size and thickness, but this effect appears to be stronger in girls than boys. This new study shows that fat mass is a strong stimulus for the accrual of cortical bone mass (hard outer layer of bone) in girls.

For the full story, Click Here